A new trial of a drug for motor neurone disease (MND) has proved to be particularly promising, though more must be done, according to experts.
Associate professor of neurology at the Massachusetts General Hospital of Harvard Medical School Dr Merit Cudkowicz presented the results of a recent trial at the MND Symposium, concluding that MND clinical trials in the US have been so far successful for a drug called KNS-760704.
Dr Michael Bozik, president and chief executive officer of Knopp Neurosciences Inc, the pharmaceutical company behind the development of KNS-760704, said: "We are very encouraged by the results presented today in Berlin and, at the same time, we're acutely aware of the work that remains to be done."
Researchers added that KNS-760704 is still in its infancy of development for patients and further testing in a large and longer-term Phase 3 trial is necessary for the establishment of necessary evidence that it is both safe and effective for patients with MND.
The MND Symposium is now in its 20th year and is the world's biggest gathering over the subject, organised by the British-based MND Association.